About bendamustine hcl
Alkylating chemotherapy medicine
Used for
- Chronic lymphocytic leukaemia
- Non-Hodgkin lymphoma
- Multiple myeloma, with other medicines
Usual adult dose
Often 100–120 mg/m² by intravenous infusion on days 1 and 2 of a 28-day cycle; regimens vary by cancer and combination.
Common side effects
- Low blood cell counts and increased infection risk
- Nausea, vomiting, diarrhoea, or constipation
- Tiredness, fever, or infusion reactions
- Rash or hair loss
Important warnings
- Can cause severe bone marrow suppression and serious infections.
- Rarely causes severe skin reactions or tumour lysis syndrome.
- May harm an unborn baby; effective contraception is required during treatment.
- Treatment requires specialist monitoring and blood tests.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is needed during treatment and for a period afterwards.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one week after the last dose.
Interactions
- Medicines that suppress bone marrow can increase blood-count problems.
- CYP1A2 inhibitors may increase bendamustine exposure.
- CYP1A2 inducers may reduce bendamustine exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.